La médecine psychédélique : renouveau des traitements d’action rapide contre la dépression ? (notice n° 1615201)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03973cam a2200505 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20260111072959.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Bottemanne, Hugo |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | La médecine psychédélique : renouveau des traitements d’action rapide contre la dépression ? |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 77 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Avec plus de 300 millions de personnes en souffrant et 20 % de la population touchée sur la vie entière, la dépression est le trouble psychiatrique le plus fréquent à travers le monde. Parmi les pistes thérapeutiques, un intérêt croissant se porte aujourd’hui sur les molécules psychédéliques, participant à l’espoir d’un renouveau de la psychopharmacologie contre la dépression résistante aux traitements. Dans cet article, nous proposons une revue narrative de l’utilisation des traitements psychédéliques dans la dépression. Nous présenterons successivement les différentes molécules psychédéliques et apparentées (kétamine, psilocybine, DMT, LSD, MDMA, mescaline) en indiquant pour chacune les niveaux de preuve de leur utilisation contre la dépression, les modalités techniques de leur administration, les pistes concernant leurs mécanismes d’action, et les perspectives de recherche. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Depression is now the most common psychiatric disorder worldwide, with more than 300 million people worldwide and 20 percent of the population affected at some point over their lifetime. There is growing interest in the use of psychedelic molecules as a treatment strategy, offering hope of a revival of psychopharmacology as a way to address treatment-resistant depression. In this article, we present a descriptive overview of the use of psychedelic treatments for depression. We examine various psychedelics and related molecules (ketamine, psilocybin, DMT, LSD, MDMA, mescaline), indicating for each the level of evidence for their use to treat depression, technical procedures for their administration, plausible mechanisms of action, and research prospects. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Con más de 300 millones de personas que la padecen y un 20% de la población afectada a lo largo de su vida, la depresión es el trastorno psiquiátrico más frecuente en todo el mundo. Entre las pistas terapeúticas, un creciente interés se vuelca hoy en las moléculas psicodélicas, lo que permite esperar un renacimiento de la psicofarmacología contra la depresión resistente a los tratamientos. En este artículo, proponemos un repaso narrativo del uso de tratamientos psicodélicos para la depresión. Presentamos sucesivamente las diferentes moléculas psicodélicas y relacionadas (ketamina, psilocibina, DMT, LSD, MDMA, mescalina), indicando para cada una de ellas el nivel de evidencia de su uso en la depresión, las métodos técnicos utilizados para su administración, las pistas sobre sus mecanismos de acción y las perspectivas de investigación. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | dépression |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | dépression résistante |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | diméthyltryptamine |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | eskétamine |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ibogaïne |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | kétamine |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | LSD |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | MDMA |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | mescaline |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | psilocybine |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | psychopharmacologie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | psychothérapie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | depression |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | dimethyltryptamine |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | esketamine |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ibogaine |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | ketamine |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | LSD |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | MDMA |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | mescaline |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | psilocybin |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | psychopharmacology |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | psychotherapy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | treatment-resistant depression |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Berkovitch, Lucie |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gasnier, Matthieu |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mallet, Luc |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | L'information psychiatrique | Volume 99 | 10 | 2024-01-04 | p. 685-692 | 0020-0204 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/revue-l-information-psychiatrique-2023-10-page-685?lang=fr&redirect-ssocas=7080">https://stm.cairn.info/revue-l-information-psychiatrique-2023-10-page-685?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux